Sponsor or institution

Clinical trials and research at Regeneron Pharmaceuticals

• 70Clinical trials
• 42Countries

Newest trials

All recruiting trials (70)

• ALN-CIDEB in adults with MASLD to see if it helps the liver

  This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.

  Recruiting at 4 sites Phase 3 Regeneron Pharmaceuticals · Miami, Florida and 3 other locations · NCT07854782

• Olatorepatide vs placebo for adults with moderate-to-severe hidradenitis suppurativa who are overweight

  This study tests whether olatorepatide can help people with hidradenitis suppurativa who are overweight or obese.

  Recruiting Phase 2 Regeneron Pharmaceuticals · The Bronx, New York · NCT07830329

• Three antibodies plus heparin in adults with end-stage kidney disease on dialysis

  This study tests three investigational antibodies (REGN9933, REGN7508, REGN9533) in adults with end-stage kidney disease on hemodialysis who are already using heparin to prevent clots.

  Recruiting Phase 1 Regeneron Pharmaceuticals · Ghent, Oost-Vlaanderen · NCT07759167

• REGN17235 for CCUS and LR-MDS with SF3B1 mutation

  This study tests REGN17235 in adults with CCUS or LR-MDS carrying an SF3B1 mutation to see if it is safe and tolerable and to get early signals of efficacy.

  Recruiting at 2 sites Phase 1 Regeneron Pharmaceuticals · Ghent and 1 other locations · NCT07753148

• Blood-clot prevention with REGN7508 and REGN9933 in people with PICC lines

  This study tests whether REGN7508 and REGN9933 can help prevent blood clots in people who have a PICC line.

  Recruiting Phase 3 Regeneron Pharmaceuticals · Tbilisi · NCT07697599

• Olatorepatide in adults who are overweight or have obesity (without diabetes) test of safety and dosing

  This study tests olatorepatide versus placebo to see if it can safely help adults who are overweight or obese lose weight at different doses.

  Recruiting at 21 sites Phase 2 Regeneron Pharmaceuticals · Mobile, Alabama and 20 other locations · NCT07685808

• REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

  This study tests REGN22530 in adults with POAG or ocular hypertension to see if it can lower eye pressure and what kind of side effects it may have.

  Recruiting Phase 1/2 Regeneron Pharmaceuticals · Deerfield Beach, Florida · NCT07675824

• Cat-allergy eye allergy treatment with REGN-2Cat and study drugs in adults and kids

  This trial tests fel d 1 monoclonal antibodies (freneslerbart and mevonlerbart) alone or together to see if they reduce cat‑induced allergic conjunctivitis symptoms compared with placebo in adults and children.

  Recruiting at 2 sites Phase 3 Regeneron Pharmaceuticals · Long Beach, California and 1 other locations · NCT07675811

• ALN-CIDEB for adults with fibrotic MASH (phase 2)

  This phase 2 study tests ALN-CIDEB versus placebo to see if it can reduce liver fat, injury, and scarring in adults with fibrotic MASH.

  Recruiting at 24 sites Phase 2 Regeneron Pharmaceuticals · Tucson, Arizona and 23 other locations · NCT07631637

• Preventing stroke and systemic embolism in adults with atrial fibrillation using REGN7508 compared with apixaban

  This trial tests REGN7508 in adults with atrial fibrillation to see if it can prevent stroke and blood clots better or as well as apixaban.

  Recruiting at 66 sites Phase 3 Regeneron Pharmaceuticals · Alexander City, Alabama and 65 other locations · NCT07626411

• Linvoseltamab with pre-dose Tocilizumab to reduce CRS in adults with relapsed/refractory multiple myeloma

  This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome in adults with relapsed/refractory multiple myeloma who have had at least four prior therapies.

  Recruiting at 7 sites Phase 4 Regeneron Pharmaceuticals · Los Angeles, California and 6 other locations · NCT07609940

• REGN15505 Alone or With Cemiplimab or REGN4336 in Advanced Prostate Cancer and Kidney Cancer

  This trial tests REGN15505 by itself or with cemiplimab or REGN4336 to see if it helps adults with metastatic castration-resistant prostate cancer or clear cell renal cell carcinoma.

  Recruiting at 6 sites Phase 1/2 Regeneron Pharmaceuticals · Goodyear, Arizona and 5 other locations · NCT07594106

• Safety and drug levels of REGN20934 in adults with overweight or obesity

  This study tests REGN20934 to see if it is safe and how it behaves in the body in adults who are overweight or have obesity.

  Recruiting Phase 1 Regeneron Pharmaceuticals · Glendale, California · NCT07594093

• Dupilumab added to standard COPD care after a flare-up

  This study tests whether adding dupilumab to usual COPD care after a severe flare requiring hospitalization can reduce the chance of another flare.

  Recruiting Phase 4 Regeneron Pharmaceuticals · Mullica Hill, New Jersey · NCT07587658

• BPX-601 CAR T-Cell Therapy for Relapsed, Metastatic Prostate Cancer

  This study tests BPX-601, a patient-derived CAR T-cell therapy, to see if it can help adults with relapsed, metastatic, castration-resistant prostate cancer.

  Recruiting at 3 sites Phase 1 Regeneron Pharmaceuticals · Atlanta, Georgia and 2 other locations · NCT07543055

• First-in-human test of REGN20423 in healthy adults and adults with eczema

  This study tests REGN20423 in healthy adults and adults with atopic dermatitis to see how it behaves in the body and whether it helps eczema symptoms.

  Recruiting at 9 sites Phase 1 Regeneron Pharmaceuticals · Birmingham, Alabama and 8 other locations · NCT07527923

• ALN-PNP with or without a GLP-1/GIP receptor agonist in adults with PNPLA3-related MASLD

  This study tests ALN-PNP, with or without tirzepatide, to see if it can reduce liver fat in adults with PNPLA3-related MASLD.

  Recruiting at 9 sites Phase 2 Regeneron Pharmaceuticals · Tucson, Arizona and 8 other locations · NCT07527910

• First-in-human test of REGN22044 safety and how it behaves in the body

  This first-in-human study will test REGN22044 in healthy adults to see if it is safe, tolerable, and how much stays in the blood after a single dose (with a placebo comparison).

  Recruiting Phase 1 Regeneron Pharmaceuticals · Ghent, Oost-Vlaanderen · NCT07526116

• Treatment and prevention of blood clots in adults with cancer

  This study tests REGN7508 against apixaban to see if it can treat and prevent blood clots in adults with or without cancer, including those with cancer-related clots in the legs and lungs.

  Recruiting at 12 sites Phase 3 Regeneron Pharmaceuticals · Hialeah, Florida and 13 other locations · NCT07493304

• REGN17372 plus linvoseltamab tolerability for adults with relapsed/refractory multiple myeloma

  This trial tests whether giving REGN17372 together with linvoseltamab is safe and what dose works for adults whose multiple myeloma has come back or stopped responding.

  Recruiting at 9 sites Phase 1/2 Regeneron Pharmaceuticals · Liverpool, New South Wales and 8 other locations · NCT07455851

• Preventing stroke and systemic embolism in adults with atrial fibrillation who can't use oral blood thinners

  This trial tests two experimental drugs, REGN7508 and REGN9933, to see if they reduce ischemic stroke or systemic embolism in adults with atrial fibrillation who cannot or choose not to take oral blood thinners.

  Recruiting at 45 sites Phase 3 Regeneron Pharmaceuticals · Dothan, Alabama and 44 other locations · NCT07430956

• REGN7508 to prevent blood clots in adults with solid tumors

  This study will test whether the experimental drug REGN7508 can prevent cancer-associated blood clots in adults with solid tumors who are receiving or about to start anticancer treatment or recovering from surgery.

  Recruiting at 27 sites Phase 3 Regeneron Pharmaceuticals · Hialeah, Florida and 27 other locations · NCT07410117

• Linvoseltamab vs. Daratumumab in high-risk smoldering myeloma

  This study tests whether linvoseltamab can delay progression to active myeloma better than daratumumab in people with high-risk smoldering multiple myeloma.

  Recruiting at 33 sites Phase 3 Regeneron Pharmaceuticals · Phoenix, Arizona and 32 other locations · NCT07393282

• Reducing blood clots after leg artery procedures with Factor XI inhibitors in adults with PAD

  This trial tests two drugs, REGN7508 and REGN9933, to see if they lower the chance of dangerous blood clots after leg artery restoration procedures in adults with peripheral artery disease.

  Recruiting at 32 sites Phase 3 Regeneron Pharmaceuticals · Alexander City, Alabama and 31 other locations · NCT07318610

• REGN13335 for adults with pulmonary arterial hypertension (PAH)

  Researchers will test whether the experimental antibody REGN13335 is safe and helps adults with pulmonary arterial hypertension who are already taking other PAH medicines.

  Recruiting at 33 sites Phase 2 Regeneron Pharmaceuticals · Aurora, Colorado and 32 other locations · NCT07318597

• ANGPTL3 inhibition for adults with diabetic kidney disease

  This study tests whether two drugs that block ANGPTL3, ALN-ANG3 and evinacumab, are safe and help adults with type 2 diabetes who have diabetic kidney disease.

  Recruiting at 57 sites Phase 2 Regeneron Pharmaceuticals · Huntsville, Alabama and 58 other locations · NCT07271186

• Mibavademab for adult women with functional hypothalamic amenorrhea

  This trial tests whether the experimental drug mibavademab helps adult women with functional hypothalamic amenorrhea make the hormones needed to resume ovulation and menstrual cycles.

  Recruiting at 10 sites Phase 2 Regeneron Pharmaceuticals · Phoenix, Arizona and 10 other locations · NCT07235917

• Eye injection of pozelimab for geographic atrophy in adults

  This study will test whether injections of pozelimab into the eye are safe and well tolerated in adults with geographic atrophy from age-related macular degeneration.

  Recruiting at 9 sites Phase 1 Regeneron Pharmaceuticals · Lakewood, Colorado and 8 other locations · NCT07230834

• Linvoseltamab alone or with carfilzomib versus standard combination regimens for adults with relapsed/refractory multiple myeloma.

  This trial tests whether linvoseltamab alone or together with carfilzomib works better than standard combination treatments for adults with relapsed or refractory multiple myeloma who have had 1–3 prior therapies.

  Recruiting at 53 sites Phase 3 Regeneron Pharmaceuticals · Atlanta, Georgia and 52 other locations · NCT07222761

• Mibavademab for adults and children with generalized lipodystrophy

  This trial will test whether mibavademab helps adults and children with generalized lipodystrophy by improving blood sugar, lowering triglycerides, and reducing liver fat while checking safety and drug levels.

  Recruiting at 9 sites Phase 3 Regeneron Pharmaceuticals · Ann Arbor, Michigan and 8 other locations · NCT07220785

• Mibavademab for obesity caused by leptin (LEP) gene mutations in children, adolescents, and adults

  This trial will try mibavademab in children, adolescents, and adults with leptin gene–related obesity to help control body weight and check safety.

  Recruiting at 3 sites Phase 3 Regeneron Pharmaceuticals · Ulm and 2 other locations · NCT07220772

• ALN-SNCA in adults with early Parkinson's disease

  This trial will test ALN-SNCA in adults with early Parkinson's disease to see if it is safe, well tolerated, and lowers α-synuclein in cerebrospinal fluid.

  Recruiting at 3 sites Phase 1 Regeneron Pharmaceuticals · Ottawa, Ontario and 2 other locations · NCT07216066

• REGN7508 versus aspirin to prevent blood clots after single-knee replacement

  This tests whether REGN7508 or aspirin better prevents blood clots in adults having elective single-knee replacement surgery.

  Recruiting at 55 sites Phase 3 Regeneron Pharmaceuticals · La Mesa, California and 56 other locations · NCT07213778

• ALN-CFB for adults with PNH who remain anemic on C5 inhibitors

  This trial will test ALN-CFB, an experimental siRNA medicine, versus placebo in adults with PNH who remain anemic despite taking a C5 inhibitor.

  Recruiting at 8 sites Phase 1/2 Regeneron Pharmaceuticals · Toronto, Ontario and 7 other locations · NCT07187401

• Safety of two new clot-preventing medicines for adults with atrial fibrillation on anticoagulation

  This trial will test two experimental medicines, REGN7508 and REGN9933, against apixaban to see if they prevent clots with acceptable bleeding risk in adults with atrial fibrillation who need long-term anticoagulation.

  Recruiting at 90 sites Phase 2 Regeneron Pharmaceuticals · Dothan, Alabama and 90 other locations · NCT07175428

• Pozelimab + cemdisiran for adults with PNH whose current treatment isn't working

  This trial tests whether combining pozelimab and cemdisiran can better reduce hemolysis in adults with PNH whose C5 inhibitor treatment isn’t controlling their disease.

  Recruiting at 20 sites Phase 3 Regeneron Pharmaceuticals · Ribeirão Preto, São Paulo and 19 other locations · NCT07154745

• Ubamatamab with or without REGN7075 for adults with advanced or metastatic non-small cell lung cancer

  This trial will try ubamatamab alone and with REGN7075 in adults with advanced or metastatic non-small cell lung cancer to see if they control the cancer and will try sarilumab to manage immune-related side effects.

  Recruiting at 18 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 17 other locations · NCT07154290

• Pozelimab safety in children 1 to 5 with CHAPLE disease

  This trial will test whether pozelimab is safe and tolerable in children ages 1 to 5 who have CHAPLE disease.

  Recruiting Phase 4 Regeneron Pharmaceuticals · Istanbul · NCT07142343

• Dupilumab for young children with eosinophilic esophagitis (food-pipe inflammation)

  This study will test whether 24 weeks of dupilumab helps infants and toddlers with active eosinophilic esophagitis improve feeding and reduce esophageal inflammation.

  Recruiting at 13 sites Phase 3 Regeneron Pharmaceuticals · Phoenix, Arizona and 12 other locations · NCT07112378

• REGN7508 versus apixaban and enoxaparin for preventing blood clots after total knee replacement

  This trial will test whether REGN7508 prevents blood clots after elective one-sided total knee replacement in adults compared with apixaban, enoxaparin, or placebo.

  Recruiting at 43 sites Phase 3 Regeneron Pharmaceuticals · Sheffield, Alabama and 46 other locations · NCT07015905

• Increasing doses of bispecific antibodies for adults with lupus nephritis

  This research will try different doses of bispecific antibody medicines in adults with lupus nephritis to see if they are safe and tolerable over long-term follow-up.

  Recruiting at 20 sites Phase 1 Regeneron Pharmaceuticals · San Francisco, California and 19 other locations · NCT06975787

• Long-term safety and effectiveness follow-up after gene-modified T cell treatment in adults

  This follows adults who received gene-modified T cell therapy to see whether the treatment stays safe and continues to work over the long term.

  Recruiting Regeneron Pharmaceuticals · Nashville, Tennessee · NCT06798298

• Ubamatamab alone and with other cancer drugs for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

  This trial will test whether ubamatamab by itself or combined with bevacizumab, cemiplimab, fianlimab, or pegylated liposomal doxorubicin helps adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 56 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 55 other locations · NCT06787612

• Adding fianlimab to cemiplimab versus cemiplimab alone for recurrent or metastatic head and neck squamous cell carcinoma

  This test sees if adding the experimental drug fianlimab to cemiplimab works better than cemiplimab alone for people with recurrent or metastatic PD-L1–positive head and neck squamous cell carcinoma.

  Recruiting at 38 sites Phase 2 Regeneron Pharmaceuticals · Los Angeles, California and 37 other locations · NCT06769698

• Testing REGN7945 with linvoseltamab for relapsed multiple myeloma

  This study is testing a new drug called REGN7945 combined with linvoseltamab to see if it helps adults with relapsed multiple myeloma better than linvoseltamab alone.

  Recruiting at 9 sites Phase 1/2 Regeneron Pharmaceuticals · Sydney, New South Wales and 8 other locations · NCT06669247

• Using cemiplimab to treat early-stage skin cancer

  This study tests if injecting a new immune treatment called cemiplimab directly into early-stage skin cancer can work better than regular surgery.

  Recruiting at 50 sites Phase 3 Regeneron Pharmaceuticals · Phoenix, Arizona and 52 other locations · NCT06585410

• Investigating a new treatment for geographic atrophy in age-related macular degeneration

  This study is testing a new treatment using two drugs to see if they can slow down the worsening of geographic atrophy in adults with age-related macular degeneration.

  Recruiting at 220 sites Phase 3 Regeneron Pharmaceuticals · Chandler, Arizona and 232 other locations · NCT06541704

• Immune cell therapy for recurrent ovarian cancer

  This study is testing a new immune cell therapy called 27T51 to see if it can help women with recurrent ovarian cancer feel better and fight their disease.

  Recruiting at 5 sites Phase 1 Regeneron Pharmaceuticals · Boston, Massachusetts and 4 other locations · NCT06469281

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called REGN10597 to see if it is safe and effective for adults with advanced solid tumors like melanoma and kidney cancer.

  Recruiting at 11 sites Phase 1/2 Regeneron Pharmaceuticals · Los Angeles, California and 10 other locations · NCT06413680

• Gene therapy for treating hemophilia B

  This study is testing a new gene therapy to see if it can help people with severe or moderately severe hemophilia B produce their own clotting factor IX and how safe it is for both adults and kids.

  Recruiting at 52 sites Phase 1/2 Regeneron Pharmaceuticals · Phoenix, Arizona and 51 other locations · NCT06379789

• Testing a new drug for ALS caused by SOD1 gene mutations

  This study is testing a new drug for adults with ALS caused by SOD1 gene mutations to see if it's safe and how it affects their symptoms and certain markers in their blood and spinal fluid.

  Recruiting at 22 sites Phase 1/2 Regeneron Pharmaceuticals · Concord, New South Wales and 21 other locations · NCT06351592

• Testing linvoseltamab for treating relapsed or refractory AL amyloidosis in adults

  This study is testing a new drug called linvoseltamab to see if it can help adults with relapsed or refractory AL amyloidosis feel better and improve their organ function.

  Recruiting at 20 sites Phase 1/2 Regeneron Pharmaceuticals · Duarte, California and 20 other locations · NCT06292780

• Combining two experimental drugs for advanced melanoma treatment

  This study is testing if a new combination of two experimental drugs can help people with advanced melanoma more than the current approved treatments.

  Recruiting at 92 sites Phase 3 Regeneron Pharmaceuticals · Chandler, Arizona and 112 other locations · NCT06246916

• Testing a new drug combination for relapsed or refractory follicular and marginal zone lymphoma

  This study is testing a new combination of drugs to see if it can help adults with relapsed or hard-to-treat follicular or marginal zone lymphoma feel better compared to standard treatment.

  Recruiting at 167 sites Phase 3 Regeneron Pharmaceuticals · Los Angeles, California and 170 other locations · NCT06149286

• Testing linvoseltamab for eliminating abnormal plasma cells in patients with high-risk MGUS or smoldering multiple myeloma

  This study is testing if a new drug called linvoseltamab can help get rid of abnormal plasma cells in patients with high-risk MGUS or smoldering multiple myeloma.

  Recruiting at 39 sites Phase 2 Regeneron Pharmaceuticals · Baltimore, Maryland and 38 other locations · NCT06140524

• Odronextamab with chemo vs rituximab with chemo in untreated DLBCL

  A new treatment approach using odronextamab plus chemotherapy is being tested to see if it works better and is as safe as rituximab plus chemotherapy for adults with newly diagnosed diffuse large B-cell lymphoma.

  Recruiting at 182 sites Phase 3 Regeneron Pharmaceuticals · Scottsdale, Arizona and 194 other locations · NCT06091865

• Testing a new drug called odronextamab for treating follicular lymphoma

  This study is testing a new drug called odronextamab to see if it can safely and effectively treat people with follicular lymphoma who haven't received treatment before.

  Recruiting at 145 sites Phase 3 Regeneron Pharmaceuticals · Tucson, Arizona and 189 other locations · NCT06091254

• Gene therapy for children with hearing loss from otoferlin mutations

  This study is testing a new gene therapy called DB-OTO to see if it can help children with hearing loss caused by specific genetic mutations improve their hearing.

  Recruiting at 16 sites Phase 1/2 Regeneron Pharmaceuticals · Los Angeles, California and 16 other locations · NCT05788536

• Long-term treatment for patients with paroxysmal nocturnal hemoglobinuria using pozelimab and cemdisiran

  This study is testing a new combination of two experimental drugs, pozelimab and cemdisiran, to see if they can safely help adults with paroxysmal nocturnal hemoglobinuria over a long period of time.

  Recruiting at 48 sites Phase 3 Regeneron Pharmaceuticals · Curitiba, Jardim Santo Andre and 49 other locations · NCT05744921

• Comparing linvoseltamab to a combination of three other cancer drugs for relapsed/refractory multiple myeloma

  This study is testing if a new drug called linvoseltamab works better than a standard combination of three other cancer drugs for adults with relapsed or refractory multiple myeloma.

  Recruiting at 19 sites Phase 3 Regeneron Pharmaceuticals · Los Angeles, California and 158 other locations · NCT05730036

• Testing a new drug combination for aggressive B-cell lymphoma

  This study is testing a new combination of two experimental drugs to see if they can help adults with aggressive B-cell lymphoma that hasn’t responded to other treatments.

  Recruiting at 20 sites Phase 1 Regeneron Pharmaceuticals · Duarte, California and 19 other locations · NCT05685173

• ALN-PNP safety and tolerability in healthy adults and adults with MASLD

  This first-in-human trial tests whether the experimental drug ALN-PNP is safe and well tolerated in healthy adults and in adults with MASLD who carry a specific PNPLA3 gene variant.

  Recruiting at 5 sites Phase 1/2 Regeneron Pharmaceuticals · Glendale, California and 5 other locations · NCT05648214

• Gene silencing treatment for chronic liver disease in genetically at-risk adults

  This study is testing a new drug to see if it can help adults at higher genetic risk for liver disease by reducing liver damage and inflammation.

  Recruiting at 36 sites Phase 2 Regeneron Pharmaceuticals · Flagstaff, Arizona and 70 other locations · NCT05519475

• Examining the effects of linvoseltamab with other cancer treatments for multiple myeloma

  This study is testing a new drug called linvoseltamab along with other cancer treatments to see how well it works and how safe it is for adults with relapsed or refractory multiple myeloma.

  Recruiting at 42 sites Phase 1 Regeneron Pharmaceuticals · La Jolla, California and 41 other locations · NCT05137054

• Investigating the safety and effectiveness of REGN4336 for advanced prostate cancer

  This study is testing a new drug called REGN4336, alone and with other treatments, to see if it can safely help adults with advanced prostate cancer shrink their tumors.

  Recruiting at 13 sites Phase 1/2 Regeneron Pharmaceuticals · Palo Alto, California and 13 other locations · NCT05125016

• Observing kidney transplant outcomes in patients treated with vonsetamig

  This study looks at how well kidney transplants work in adults who were treated with vonsetamig before their transplant to see how it affects their health afterward.

  Recruiting at 8 sites Regeneron Pharmaceuticals · Los Angeles, California and 8 other locations · NCT05106387

• Investigating the safety and effectiveness of REGN5668 with other drugs for advanced ovarian and uterine cancers

  This study is testing if a new drug called REGN5668, used with other medications, can safely help people with advanced ovarian or uterine cancers.

  Recruiting at 27 sites Phase 1/2 Regeneron Pharmaceuticals · Duarte, California and 27 other locations · NCT04590326

• Evaluating the safety and effectiveness of REGN5678 alone or with cemiplimab for advanced prostate and kidney cancer

  This study is testing if a new drug called REGN5678, alone or with another drug called cemiplimab, can safely shrink tumors in adults with advanced prostate and kidney cancer.

  Recruiting at 26 sites Phase 1/2 Regeneron Pharmaceuticals · Gilbert, Arizona and 26 other locations · NCT03972657

• Testing REGN5458 for patients with relapsed or refractory multiple myeloma

  This study is testing a new drug called REGN5458 to see if it can safely help adults with relapsed or refractory multiple myeloma who have few treatment options.

  Recruiting at 25 sites Phase 1/2 Regeneron Pharmaceuticals · Miami, Florida and 39 other locations · NCT03761108

• Treatment for recurrent ovarian and other MUC16+ cancers using REGN4018 and cemiplimab

  This study is testing if a new treatment combining REGN4018 and cemiplimab can help adults with recurrent ovarian and other MUC16+ cancers feel better when other options have run out.

  Recruiting at 49 sites Phase 1/2 Regeneron Pharmaceuticals · Birmingham, Alabama and 53 other locations · NCT03564340

Quick answers

How many clinical trials run by Regeneron Pharmaceuticals are recruiting right now?

70, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 42 countries. The most sites are in United States (57 trials), Spain (20 trials), United Kingdom (19 trials), South Korea (19 trials), France (16 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 24, Phase 1/2: 16, Phase 2: 13, Phase 1: 12. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →